Trials in set up

These are brief descriptions of trials currently in set up.  Information will be updated as soon as details are finalised, centres are known and are the trials are starting.

An open-label, first line Phase II trial for inoperable, recurrent and metastatic cholangiocarcinoma (intra- and extrahepatic) and gall bladder cancer patients.

This will be a single arm study of first line Pembrolizumab and Gemcitabine/Cisplatin.

All patients on this trial will receive the immunotherapy drug Pembrolizumab in addition to the Gemcitabine/Cisplatin chemotherapy.

For more information on this trial, see:

A Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with locally advanced/borderline resectable proximal biliary tract cancer.

This study will investigate the possible benefit of neo-adjuvant chemotherapy in those cholangiocarcinoma patients diagnosed with borderline resectability.

For more information see:

FOENIX-CCA3: An open-label, randomized phase 3 study of futibatinib (TAS-120) versus gemcitabine-cisplatin chemotherapy as first-line treatment for patients with advanced cholangiocarcinoma harbouring fibroblast growth factor receptor 2 gene rearrangements (FOENIX-CCA3)

This study will compare chemotherapy (CisGem) with an FGFR-inhibitor in FGFR2-altered patients and will require prior analysis of a tumour biopsy to determine that there is the appropriate FGFR-alteration

Back to previous page